Selected biotechnology-related patents issued by the U.S.Patent and Trademark Office on Nov. 19.

U.S. Class: 424--85.2Patent No.: 5,066,489Assignee: Cetus Corp.Claims/Description: 33 claims for the use of both interleukin 2and the cytotoxic alkylating agent dacarbazine to treatmelanomas.

U.S. Class: 435--5Patent No.: 5,066,579Assignee: Genelabs Inc.Claims/Description: 6 claims for an HTLV-I envelope peptideand for its use to identify antibodies produced in response toHTLV-I infection.

U.S. Class: 435--91Patent No.: 5,066,584Assignee: Cetus Corp.Claims/Description: 7 claims for the use of the polymerasechain reaction (PCR) to produce single-stranded DNA molecules.

U.S. Class: 435--172.3Patent No.: 5,066,589Assignee: U. of OklahomaClaims/Description: 32 claims for expression vectors containingDNA sequences that encode streptokinase.

U.S. Class: 435--180Patent No.: 5,065,590Assignee: Ajinomoto Co. Inc., TokyoClaims/Description: 11 claims for a modified superoxidedismutase with poly (alkylene) molecules on both ends.

U.S. Class: 435--189Patent No.: 5,066,591Assignee: Chiron Corp.Claims/Description: 2 claims for a non-acetylated humancopper/zinc superoxide dismutase.

U.S. Class: 435--240.2Patent No.: 5,066,592Assignee: Temple UniversityClaims/Description: 5 claims for trigramin, a protein thatinhibits platelet aggregation.

U.S. Class: 435--240.27Patent No.: 5,066,593Assignee: Salk Institute for Biological StudiesClaims/Description: 9 claims for antibodies that bind to rabiesvirus coat glycoproteins.

U.S. Class: 435--240.4Patent No.: 5,066,594Assignee: DNA Plant Technology Corp.Claims/Description: 41 claims for a method to stabilizegerminated pollen grains.

U.S. Class: 435--240.45Patent No.: 5,066,595Assignee: Sungene Technologies Corp.Claims/Description: 54 claims for a method to increase theamount of lysine in corn plant seeds.

U.S. Class: 530--324Patent No.: 5,066,782Assignee: Institut Pasteur, ParisClaims/Description: 8 claims for HIV-2 antigens that can detectantibodies produced in response to HIV-2 infection.

U.S. Class: 530--328Patent No.: 5,066,783Assignee: Unassigned; inventors from Quebec, CanadaClaims/Description: 1 claim for polypeptides to treat herpesinfections.

U.S. Class: 530--345Patent No.: 5,066,785Assignee: City of HopeClaims/Description: 10 claims for a method to sequenceproteins from the carboxyl terminus.

U.S. Class: 530--388Patent No.: 5,066,789Assignee: NeoRx Corp.Claims/Description: 4 claims for a targeted delivery system inwhich a drug or diagnostic agent is joined to the targetingcompound by a hydrazone linker.

U.S. Class: 536--27Patent No.: 5,066,792Assignee: U. of TexasClaims/Description: 3 claims for a nucleic acid probe to detectspecific human leukemias such as chronic myelogenousleukemia.

U.S. Class: 800--230Patent No.: 5,066,830Assignee: DNA Plant Technology Corp.Claims/Description: 17 claims for a pepper plant that producesfruit with a reduced number of seeds.

-- Compiled by Carol Talkington Verser, Ph.D., of Sheridan Ross& McIntosh, Denver

(c) 1997 American Health Consultants. All rights reserved.